JY
IRD

Jeff Yass’s Opus Genetics IRD Stock Holding History

Jeff Yass’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,600
Closed -$73K – 14136
2022
Q1 		$73K Buy
22,600
+11,200
+98% +$38.3K ﹤0.01% 12109
2021
Q4 		$43K Sell
11,400
-56,000
-83% -$225K ﹤0.01% 12623
2021
Q3 		$347K Buy
+67,400
New +$311K ﹤0.01% 10267

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's IRD Position: Q2 2026 in Review

Jeff Yass reduced its Opus Genetics (IRD) stake by 76% in Q2 2026, selling an estimated $2.92M and leaving 196,897 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #8756.

Jeff Yass first reported a position in IRD in Q4 2014 and has held it in 24 quarters since. The position peaked at $3.75M in Q1 2026. 102 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Jeff Yass held 196,897 shares of Opus Genetics worth $809K as of Q2 2026.
  • Jeff Yass sold 626,486 Opus Genetics shares in Q2 2026, an estimated $2.92M.
  • Opus Genetics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8756 holding.
  • Jeff Yass first reported a position in Opus Genetics in Q4 2014 and has held it in 24 quarters since.
  • Jeff Yass's Opus Genetics position peaked at $3.75M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.